Q3 2025 Earnings Call Transcript November 6, 2025 Moderna, Inc. beats earnings expectations. Reported EPS is $-0.51282, expectations were $-2.15. Operator: Good day, and thank you for standing by.
Fifers planning to visit loved ones in hospital have been urged to make sure they are free of coughs, colds and other winter ...
Health officials have issued a '48-hour' plea to parents following a rise of norovirus cases in recent weeks, particularly ...
Get the latest insights from Moderna's Q3 2025 earnings call: revenue guidance updates, cost reduction highlights, and pipeline progress.
Moderna reported third-quarter financial results on Thursday. The transcript from the company's earnings call has been provided below.
First, the phase 3 trial of Moderna’s norovirus vaccine had to endure a clinical hold. | First, the phase 3 trial of ...
1d
Flu warning as Surrey hospital trust fears this year's outbreak 'could be even worse' than last year
The St George's, Epsom and St Helier Hospital Group (GESH) NHS Trust is urging people to get their flu jabs as they "brace for a repeat" of last winter. This saw the trust be hit by a flood of flu ...
Reports third quarter revenue of $1.0 billion, GAAP net loss of $ (0.2) billion and GAAP EPS of $ (0.51) Improves 2025 ...
Dynavax is paying $30 million upfront for global rights to Vaxart’s investigational oral COVID-19 vaccine candidate, positioning the biotech to see phase 2b data before placing a bigger bet on the ...
Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, and Vaxart, Inc. (OTCQX: VXRT), a clinical-stage ...
A recent Indian Council of Medical Research (ICMR) study made some shocking revelations. It discovered that one in nine ...
As the air turns colder, wintertime illnesses are beginning to spread. In recent weeks, both Riverview Health and Eskenazi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback